中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2010年
4期
300-307
,共8页
骨质疏松症%推拿%研究进展
骨質疏鬆癥%推拿%研究進展
골질소송증%추나%연구진전
Osteoporosis%Massage therapy%Research progress
随着我国人口的老龄化,骨质疏松症的发病率日益增加.目前西医对该病的治疗副作用较大,疗效不太理想.而中医药治疗该病副作用小,能够修复骨质,提高骨量,起到标本兼治、综合治疗的目的 .推拿疗法是一种纯绿色的物理治疗,无任何毒副作用,舒适而无痛苦.未来几年,推拿治疗骨质疏松症必将成为医学界研究的热点.现有研究证实,推拿确实能够缓解骨质疏松所致的骨痛、腰背痛等症状,改善患者的衰老症状及ADL生活质量水平,能够提高骨质疏松患者的骨密度,降低血清骨钙素(s-BGP)和尿羟脯氨酸/肌酐(U-Hyp/Cr)比值,降低IL-1β、IL-6水平,对绝经后骨质疏松症(Ⅰ型)及老年性骨质疏松症(Ⅱ型)均有效.
隨著我國人口的老齡化,骨質疏鬆癥的髮病率日益增加.目前西醫對該病的治療副作用較大,療效不太理想.而中醫藥治療該病副作用小,能夠脩複骨質,提高骨量,起到標本兼治、綜閤治療的目的 .推拿療法是一種純綠色的物理治療,無任何毒副作用,舒適而無痛苦.未來幾年,推拿治療骨質疏鬆癥必將成為醫學界研究的熱點.現有研究證實,推拿確實能夠緩解骨質疏鬆所緻的骨痛、腰揹痛等癥狀,改善患者的衰老癥狀及ADL生活質量水平,能夠提高骨質疏鬆患者的骨密度,降低血清骨鈣素(s-BGP)和尿羥脯氨痠/肌酐(U-Hyp/Cr)比值,降低IL-1β、IL-6水平,對絕經後骨質疏鬆癥(Ⅰ型)及老年性骨質疏鬆癥(Ⅱ型)均有效.
수착아국인구적노령화,골질소송증적발병솔일익증가.목전서의대해병적치료부작용교대,료효불태이상.이중의약치료해병부작용소,능구수복골질,제고골량,기도표본겸치、종합치료적목적 .추나요법시일충순록색적물리치료,무임하독부작용,서괄이무통고.미래궤년,추나치료골질소송증필장성위의학계연구적열점.현유연구증실,추나학실능구완해골질소송소치적골통、요배통등증상,개선환자적쇠로증상급ADL생활질량수평,능구제고골질소송환자적골밀도,강저혈청골개소(s-BGP)화뇨간포안산/기항(U-Hyp/Cr)비치,강저IL-1β、IL-6수평,대절경후골질소송증(Ⅰ형)급노년성골질소송증(Ⅱ형)균유효.
With the aging of our population,the incidence of osteoporosis is increasing.At present,the side effects of western medicine on the treatment of this disease is big,efficacy is less than ideal.The side effects of traditional Chinese medicine on the treatment of this disease is small,be able to repair the sclerotin and improve the bone mass,be able to achieve the purpose of symptoms and root cause,and achieve the purpose of comprehensive treatment.Massage therapy is a pure green physical therapy,without any toxic side effects and comfort without pain.The next few years,Massage therapy treatment osteoporosis will become the hot medical research.The current study confirmed that,Massage can really ease the ostealgia and waist-back pain and other symptoms caused by osteoporosis,Improvement in patients with symptoms of aging and ADL the quality,can increase BMD in osteoporosis patients,Lowering the s-BGP and U-Hyp/Cr,Lowering the IL-1β and IL-6.Pairs of postmenopausal osteoporosis (Ⅰ) and senile osteoporosis (Ⅱ) are valid.